University of Toronto, Toronto General Hospital, Department of Medicine, Ontario, Canada.
Expert Opin Pharmacother. 2011 Jun;12(8):1269-83. doi: 10.1517/14656566.2011.549126. Epub 2011 Feb 10.
Ascites is a common complication of advanced cirrhosis that has a significant negative impact on survival. This review updates the reader on the medical management of ascites.
This review explores the pathophysiology of ascites formation in cirrhosis; the current mainstays of medical management (treating the underlying cause of cirrhosis, avoiding nephrotoxic agents, sodium restriction, and combination diuretic therapy); potential novel agents, such as vasoconstrictors and vaptans; and albumin infusions. The literature research covers all aspects of medical management of ascites from the English literature, concentrating on publications from the past 10 years. It provides a thorough understanding of how the correction of pathophysiology of ascites formation helps to improve ascites; knowledge on the monitoring of patients with cirrhosis and ascites receiving medical management, and on prophylaxis against potentially life-threatening complication such as spontaneous bacterial peritonitis; and potential new treatments for ascites.
Management of patients with cirrhosis and ascites requires careful attention to fluid and electrolyte balance and avoidance of complications. Recognition of refractory ascites allows for the use of second-line treatments. All patients with cirrhosis and ascites should be considered for liver transplantation.
腹水是晚期肝硬化的常见并发症,对生存有显著的负面影响。本篇综述更新了读者对腹水的医学管理的认识。
本篇综述探讨了肝硬化腹水形成的病理生理学;目前腹水的主要医学治疗方法(治疗肝硬化的根本原因、避免使用肾毒性药物、限制钠摄入和联合使用利尿剂治疗);潜在的新型药物,如血管收缩剂和血管加压素受体拮抗剂;以及白蛋白输注。文献研究涵盖了从英语文献中腹水的医学管理的各个方面,重点关注过去 10 年的出版物。它提供了对腹水形成的病理生理学的纠正如何有助于改善腹水的深入理解;了解接受医学治疗的肝硬化和腹水患者的监测,以及预防潜在危及生命的并发症(如自发性细菌性腹膜炎)的知识;以及腹水的潜在新治疗方法。
肝硬化和腹水患者的管理需要仔细注意液体和电解质的平衡,并避免并发症。认识到难治性腹水可以使用二线治疗。所有肝硬化和腹水患者都应考虑进行肝移植。